Table 2.

Distribution of EGFR, HIF1α,VEGF-A and CAIX for prostate cancer patients ( n  = 103) treated with RT, with or without ADT

	n (%)
EGFR
negative	42(40.8)
weak	35 (34.0)
strong	26 (25.2)
HIF1α (nuclear staining)
No staining	9 (8.7)
< 10%	3 (2.9)
10 – 50%	9 (8.7)
> 50	81 (78.6)
NA	1 (1)
VEGF-A
low	27 (26.2)
high	76 (73.8)
CA-IX
negative	103 (100.0)
positive	0 (0)

RT radiotherapy; ADT anti-androgen deprivation therapy; NA not assessable.